Validated Phenotypic Approach to Neuropsychiatric Drug Discovery. Drug Development & Delivery, March 2019 Vol. 19, No. 2: 46-49. For more info . . .
Zhang H.K, Eaton J.B, Y LF, Nys M, Mazzolari A, Elk R, Smit AB, Alexandrov V, Hanania T, Sabath E, Fedolak A, Brunner D, Lukas R.J, Vistoli G, Ulens C, Kozikowski A.P.
Insights into the Structural Determinants Required for High Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors; An Integrated Approach to Behaviorally Active Nicotinic Ligands.. J.Med.Chem. 2012 8028-8037
Brunner, D, Alexandrov V, Caldarone B, Hanania T, Lowe D, Schneider J, Chandrasekhar J.
Behavior-Based Screening as an Approach to Polypharmacological Ligands, in Polypharmacology in Drug Discovery. (Peters, J.-U., Ed.), pp 301-309, John Wiley & Sons, Inc., Hoboken, New Jersey. 2012
Roberds SL, Filippov I, Alexandrov V, Hanania T, Brunner D.
Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms. Front Neurosci. 2011 5, 103
Brunner D, Balci F, Ludvig EA.
Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration. Behav Processes. 2011 89, 187-195
Houghten RA, Pinilla C, Giulianotti MA, Appel JR, Dooley CT, Nefzi A, Ostresh JM, Yu Y, Maggiora GM, Medina F JL, Brunner D, Schneider J.
Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. J Comb Chem 2008, 10, 3-19.
Brunner D, Nestler E, Leahy E.
In need of high-throughput behavioral systems. Drug Discov Today. 2002, 7, S107-12.